Apotex Execs Avoid Criminal Charges Under DOJ Deferred Prosecution Agreement

While former Sandoz and Heritage execs were charged in the government's generic price-fixing probe, Apotex and its employees will apparently escape such fate if they abide by the terms of DOJ agreement; company admits to fixing price of pravastatin and agrees to pay $24.1m criminal penalty.

WASHINGTON, DC - MARCH 2018: Headquarters of the U.S. Justice Department. Art Deco aluminum torcheres at doorway. Renamed the Robert F. Kennedy Department of Justice Building in 2001.
DOJ charges fourth company in generic pricing probe and defers prosecution

Apotex Inc. freed both itself and its employees from the US Department of Justice's probe of the generics industry under a three-year deferred prosecution agreement to resolve the DOJ's charge that it fixed the price of the cholesterol medication pravastatin.

Under the agreement, announced on 7 May, Apotex admitted that it conspired with other generic drug sellers to artificially...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Generics

More from Biosimilars & Generics